TrialPath
Multiple sclerosis · San Antonio

Multiple sclerosis clinical trials in San Antonio

2 recruiting multiple sclerosis studies within range of San Antonio. Click any trial for full eligibility criteria and contact info.

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Recruiting

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

PhasePhase 3
TypeInterventional
Age18 Years – 60 Years
WherePhoenix, Arizona, United States + 97 more
SponsorZenas BioPharma (USA), LLC
▾Tap for details
Apply

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292 · Multiple Sclerosis
Recruiting

This is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: The study intervention duration will be 48 weeks (12 months) for Parts A and B combined. Optional Part C will last until the initiation of a long term safety study for Frexalimab.The follow up duration after the end of study intervention (in case of discontinuation) will be 6 months. The number of scheduled visits (Parts A and B) will be 17 for participants receiving frexalimab SC or IV, with an on-site visit frequency of every month between Week 4 and Week 24 in Part A, then every 1 to 3 months in Part B, then every 6 months in Part C. Participants discontinuing treatment before the End of Study will have an additional 3 follow-up visits.

PhasePhase 3
TypeInterventional
Age18 Years – 60 Years
WhereCullman, Alabama, United States + 67 more
SponsorSanofi
▾Tap for details
Apply